Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, discusses the status of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).

The first FDA approval will likely be in pediatric ALL, Shah says. However, in the adult patients with ALL, researchers are closely behind.

However, several pharmaceutical companies have been entering the space and are actively conducting clinical trials with these agents. These therapies have the ability to produce durable remissions and improve survival, Shah says.

Videos

Dr. Shah on Status of CAR T-cell Therapies in ALL

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses the impact of the approval of frontline bortezomib for the treatment of mantle cell lymphoma (MCL).

Shah admits he is struggling in treating patients with MCL with bortezomib in the frontline setting. It is not a treatment option often used at Moffitt Cancer Center due to the neuropathy associated with it. Though administering bortezomib subcutaneously has helped lessen the grade 3 adverse event, practitioners still see grade 2 neuropathy.

An overall issue with bortezomib, Shah says, involves the phase III study comparing bortezomib to rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) for patients ineligible for bone marrow transplantation. The study was done without maintenance therapy.

Shah is unsure if maintenance will involve single-agent rituximab. An ongoing, randomized study is comparing bendamustine and rituximab to bendamustine, bortezomib and rituximab. A second randomization is comparing maintenance with rituximab to lenalidomide. 

Bijal D. Shah, MD

Articles

Dr. Shah on Status of CAR T-cell Therapies in ALL

Dr. Bijal Shah on Bortezomib's Impact on Treatment of MCL